Read more

January 08, 2021
1 min read
Save

Kala launches Eysuvis for short-term dry eye treatment

Eysuvis is now available for the short-term treatment of dry eye disease, according to a press release from Kala Pharmaceuticals.

Eysuvis uses Kala’s proprietary Ampplify mucus-penetrating particle drug delivery technology for enhanced penetration of loteprednol etabonate into target ocular surface tissue to treat signs and symptoms of dry eye disease. The treatment also offers a favorable tolerability and safety profile and has the potential to completement existing therapies, the release said.

“We are excited to announce our second product launch in 2 years, with Eysuvis now available in the United States as the first approved prescription therapy specifically indicated for the short-term treatment of dry eye disease,” Mark Iwicki, chairman, president and CEO of Kala, said in the release.

The FDA approved Eysuvis in October 2020.